Physician profile
Rupinder Kaur
NPI 1740213982
$12,648.53
in general payments reported to CMS, 2019-2025
38 companies · $1,731 in 2025
The $1,731 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $963 · 2020: $1,268 · 2021: $2,116 · 2022: $2,125 · 2023: $2,586 · 2024: $1,860 · 2025: $1,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,150 · Education: $26.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,150.49 |
| Education | $26.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,967.68 | 2019-2025 | Spravato |
| Abbvie INC. | $1,813.40 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,054.17 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $986.65 | 2020-2025 | Caplyta |
| Alkermes, INC. | $930.57 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Allergan, INC. | $754.04 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $668.71 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $636.72 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $452.65 | 2020-2025 | Ingrezza |
| Tris Pharma INC | $408.62 | 2022-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $339.81 | 2020-2023 | Belsomra |
| Supernus Pharmaceuticals, INC. | $312.55 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $277.50 | 2022-2025 | Sunosi, Auvelity |
| Vanda Pharmaceuticals INC. | $199.79 | 2021-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $198.07 | 2022-2024 | Loreev Xr, Sertraline Hcl |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $196.74 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $194.88 | 2021 | |
| Indivior INC. | $183.86 | 2019-2024 | Sublocade |
| Ironshore Pharmaceuticals INC. | $119.16 | 2019-2023 | Jornay Pm |
| Noven Therapeutics, LLC | $107.72 | 2021-2024 | Xelstrym, Secuado |
| Lundbeck LLC | $106.02 | 2019-2023 | Rexulti |
| Validus Pharmaceuticals LLC | $93.15 | 2020-2024 | Equetro |
| Avanir Pharmaceuticals, INC. | $91.13 | 2021-2022 | |
| Neos Therapeutics, Lp | $83.84 | 2022-2024 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $75.07 | 2022-2024 | Quviviq |
| Vertical Pharmaceuticals, LLC | $64.33 | 2019-2020 | |
| Orexo US, INC. | $55.63 | 2019-2022 | |
| Adlon Therapeutics L.P. | $50.41 | 2019-2020 | |
| Novo Nordisk INC | $43.81 | 2019 | |
| Bausch Health US, LLC | $33.47 | 2022-2023 | Aplenzin, Wellbutrin |
| Corium, LLC | $28.33 | 2021-2024 | Azstarys |
| Currax Pharmaceuticals LLC | $27.25 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.29 | 2025 | Cobenfy |
| Eisai INC. | $16.50 | 2020 | |
| Braeburn INC. | $14.59 | 2023 | Brixadi |
| Biohaven Pharmaceuticals, INC. | $14.19 | 2021 | |
| Avion Pharmaceuticals | $14.06 | 2023 | Methylphenidate Hydrochloride |
| Shire North American Group INC | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupinder Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.